Pretomanid: XDR-TB may soon become easily treatable
Though the total number of people with XDR-TB and treatment intolerant or non-responsive MDR-TB who will require the new anti-TB drug Pretomanid may not be high, these are people who…
A Science and Technology Blog
Though the total number of people with XDR-TB and treatment intolerant or non-responsive MDR-TB who will require the new anti-TB drug Pretomanid may not be high, these are people who…
When used in combination with bedaquiline and linezolid, the newly approved pretomanid drug for MDR-TB and XDR-TB had an overall treatment success rate of about 90%. Besides better effectiveness, the…
Treating young children afflicted with drug-sensitive TB disease will no longer be the same. After years of neglect, the availability of flavoured, easily dissolvable first-line TB drugs in correct doses…
For the first time, child-friendly TB drugs for first-line medication in a fixed-dose combination was launched by TB Alliance, UNITAID and WHO at the 46th Union World Conference on Lung…
A novel drug combination (PaMZ) designed to treat both drug-sensitive and MDR-TB, including those who are HIV positive, is advancing to the crucial Phase III human clinical trial. If all…
Dr. Mel Spigelman, President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance) is regarded as one of the world’s leading experts in tuberculosis and…